The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. ⋯ Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis. (ClinicalTrials.gov number, NCT00048542.)
-
Editorial Comment
Human papillomavirus vaccination--reasons for caution.